Lexicon Pharmaceuticals, Inc. (LXRX)
1.82
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
1.825
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Enterprise Value : 678.42M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 678.42M |
| October 01, 2026 | 678.42M |
| September 30, 2026 | 702.89M |
| September 29, 2026 | 705.11M |
| September 28, 2026 | 714.01M |
| September 25, 2026 | 667.29M |
| September 24, 2026 | 696.21M |
| September 23, 2026 | 785.20M |
| September 22, 2026 | 838.59M |
| September 21, 2026 | 776.30M |
| September 18, 2026 | 780.75M |
| September 17, 2026 | 774.08M |
| September 16, 2026 | 767.40M |
| September 15, 2026 | 762.95M |
| September 14, 2026 | 749.61M |
| September 11, 2026 | 758.50M |
| September 10, 2026 | 767.40M |
| September 09, 2026 | 825.25M |
| September 08, 2026 | 860.84M |
| September 04, 2026 | 865.29M |
| September 03, 2026 | 874.19M |
| September 02, 2026 | 865.29M |
| September 01, 2026 | 843.04M |
| August 31, 2026 | 869.74M |
| August 28, 2026 | 887.54M |
| Date | Value |
|---|---|
| August 27, 2026 | 900.88M |
| August 26, 2026 | 896.44M |
| August 25, 2026 | 909.78M |
| August 24, 2026 | 900.88M |
| August 21, 2026 | 891.99M |
| August 20, 2026 | 838.59M |
| August 19, 2026 | 940.93M |
| August 18, 2026 | 945.38M |
| August 17, 2026 | 909.78M |
| August 14, 2026 | 900.88M |
| August 13, 2026 | 909.78M |
| August 12, 2026 | 914.23M |
| August 11, 2026 | 949.83M |
| August 10, 2026 | 936.48M |
| August 07, 2026 | 967.63M |
| August 06, 2026 | 918.68M |
| August 05, 2026 | 958.73M |
| August 04, 2026 | 976.52M |
| August 03, 2026 | 905.33M |
| July 31, 2026 | 896.44M |
| July 30, 2026 | 909.78M |
| July 29, 2026 | 900.88M |
| July 28, 2026 | 909.78M |
| July 27, 2026 | 860.84M |
| July 24, 2026 | 887.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bristol Myers Squibb Co. | 158.92B |
| ANI Pharmaceuticals, Inc. | 1.893B |
| Corcept Therapeutics, Inc. | 12.24B |
| Veru, Inc. | 19.69M |
| Johnson & Johnson | 644.86B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.78M |
| Revenue (Quarterly) | 0.692M |
| Total Expenses (Quarterly) | 32.47M |
| EPS Diluted (Quarterly) | -0.0726 |
| Gross Profit Margin (Quarterly) | 79.62% |
| Profit Margin (Quarterly) | -4.59K% |
| Earnings Yield | -8.41% |
| Normalized Earnings Yield | -8.028 |